Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 38% Improvement Relative Risk Cilli et al. Favipiravir for COVID-19 LATE TREATMENT Is late treatment with favipiravir beneficial for COVID-19? Retrospective 46 patients in Turkey Lower mortality with favipiravir (not stat. sig., p=0.51) Cilli et al., Respiratory Medicine and Research, doi:10.1016/j.resmer.2022.100900 Favors favipiravir Favors control
Characteristics and outcomes of COVID-19 patients with IPF: A multi-center retrospective study
Cilli et al., Respiratory Medicine and Research, doi:10.1016/j.resmer.2022.100900
Cilli et al., Characteristics and outcomes of COVID-19 patients with IPF: A multi-center retrospective study, Respiratory Medicine and Research, doi:10.1016/j.resmer.2022.100900
Mar 2022   Source   PDF  
  All Studies   Meta
Retrospective 46 idiopathic pulmonary fibrosis patients with COVID-19 in Turkey, showing lower mortality with favipiravir in unadjusted results, without statistical significance. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 37.5% lower, RR 0.62, p = 0.51, treatment 5 of 23 (21.7%), control 8 of 23 (34.8%), NNT 7.7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cilli et al., 3 Mar 2022, retrospective, Turkey, peer-reviewed, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Abstract: Respir. Med and Res 81 (2022) 100900 Available online at ScienceDirect Original article Characteristics and outcomes of COVID-19 patients with IPF: A multi-center retrospective study Aykut Cillia,*, Ismail Hantab, Fatih Uzera, Funda Coskunc, Can Sevincd, Pelin Pınar Denizb, Mehmet Parlaka, Ersoy Altunokb, Kemal Can Tertemizd, Ahmet Ursavasc a Department of Respiratory Disease, Akdeniz University, Antalya, Turkey Department of Respiratory Disease, Cukurova University, Adana, Turkey c Department of Respiratory Disease, Uludag University, Bursa, Turkey d Department of Respiratory Disease, Dokuz Eylul University, Izmır, Turkey b A R T I C L E I N F O Article History: Received 16 November 2021 Revised 18 February 2022 Accepted 25 February 2022 Available online 3 March 2022 Key words: Interstitial lung disease Idiopathic pulmonary fibrosis Outbreak Pandemic SARS-CoV-2 A B S T R A C T Background: There are few data on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID19) infection in patients with idiopathic pulmonary fibrosis (IPF). The objective of this study is to describe the characteristics and outcomes of IPF patients confirmed COVID-19 infection. Methods: In this retrospective, multi-center, cohort study, patients from 4 hospital medical records with known IPF and a COVID-19 diagnosis were identified. Demographic and clinical outcome data were abstracted through a review of electronic medical records. Results: Records for 46 patients with IPF and COVID-19 were abstracted. The mean age was 65§ 10 years. The most common symptom was dyspnea, followed by fever and cough. Ground-glass opacities (n = 35, 83.3%) and consolidations (n = 11, 26.1%) were the main imaging features of the disease in thorax computed tomography (CT). Twenty-four patients (52.1%) required hospitalization. Among the hospitalized patients, 16 (66.6%) were admitted to the intensive care unit (ICU), and 10 (41.6%) underwent invasive mechanical ventilation. Thirteen patients (28.2%) died of COVID-19 complications. Mortality rate was significantly associated with lower DLCO/VA, long term oxygen therapy and consolidation finding on CT of thorax (p<0.05). On multivariable analysis, neither factor was associated with hospitalization or mortality. Conclusions: IPF patients represent a vulnerable population for COVID-19, according to the high rate of hospitalization, ICU requirement, and mortality rate. Measures to minimize the risk of COVID-19 infection remain key to protect IPF patients. © 2022 SPLF and Elsevier Masson SAS. All rights reserved.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop